Vildagliptin: the first innovative DDP-4 inhibitor
A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presenteda...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9ab778ef5d4d43219fab7fe831ded6ca |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9ab778ef5d4d43219fab7fe831ded6ca |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9ab778ef5d4d43219fab7fe831ded6ca2021-11-14T09:00:15ZVildagliptin: the first innovative DDP-4 inhibitor2072-03512072-037810.14341/2072-0351-5499https://doaj.org/article/9ab778ef5d4d43219fab7fe831ded6ca2010-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5499https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presentedalong with the results of its comparison with another agent of this group (sitagliptin).Edvin VillkhauerEndocrinology Research Centrearticledipeptidyl peptidase-4 inhibitordpp-4vildagliptinnovartisNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 3, Pp 118-120 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
dipeptidyl peptidase-4 inhibitor dpp-4 vildagliptin novartis Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
dipeptidyl peptidase-4 inhibitor dpp-4 vildagliptin novartis Nutritional diseases. Deficiency diseases RC620-627 Edvin Villkhauer Vildagliptin: the first innovative DDP-4 inhibitor |
| description |
A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presentedalong with the results of its comparison with another agent of this group (sitagliptin). |
| format |
article |
| author |
Edvin Villkhauer |
| author_facet |
Edvin Villkhauer |
| author_sort |
Edvin Villkhauer |
| title |
Vildagliptin: the first innovative DDP-4 inhibitor |
| title_short |
Vildagliptin: the first innovative DDP-4 inhibitor |
| title_full |
Vildagliptin: the first innovative DDP-4 inhibitor |
| title_fullStr |
Vildagliptin: the first innovative DDP-4 inhibitor |
| title_full_unstemmed |
Vildagliptin: the first innovative DDP-4 inhibitor |
| title_sort |
vildagliptin: the first innovative ddp-4 inhibitor |
| publisher |
Endocrinology Research Centre |
| publishDate |
2010 |
| url |
https://doaj.org/article/9ab778ef5d4d43219fab7fe831ded6ca |
| work_keys_str_mv |
AT edvinvillkhauer vildagliptinthefirstinnovativeddp4inhibitor |
| _version_ |
1718429597367795712 |